Gallagher Named Editor in Chief of Contagion.
M2 PHARMA-November 3, 2017-Gallagher Named Editor in Chief of Contagion
(C)2017 M2 COMMUNICATIONS
- US-based infectious disease-focused publication Contagion has appointed Jason Gallagher, Pharm.D., FCCP, FIDSA, BCPS, as its editor in chief, the company said.
Gallagher hails from the School of Pharmacy at Temple University in Pennsylvania where he serves as the director of the residency program and clinical professor and clinical pharmacy specialist in infectious disease.
Throughout his esteemed career, Gallagher has been responsible for publications, abstracts and book chapters.
He has been the president of the Society of Infectious Diseases Pharmacists and has had leadership positions in other societies.
Gallagher is an author of Antibiotics Simplified, which is it its fourth edition, and currently serves on the Infectious Diseases Specialty Council of the board of Pharmacy Specialties.
His research interests focus on pharmacotherapy of resistant infections, antimicrobial clinical pharmacodynamics, and antibiotic stewardship.
As editor in chief, Gallagher will work closely with Contagion's editorial team to deliver information about recent medical developments and research in infectious diseases.
Additionally, Dr. Gallagher will offer exclusive insights about emerging trends in the infectious disease community.
Contagion is a news resource covering all areas of infectious disease.
Through its website, quarterly journal, email newsletters, social media outlets and Outbreak Monitor, it provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment and prevention of infectious diseases.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 3, 2017|
|Previous Article:||BrainStorm names Eyal Rubin as CFO.|
|Next Article:||Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab.|